Immix Biopharma Statistics
Total Valuation
Immix Biopharma has a market cap or net worth of $57.94 million. The enterprise value is $43.08 million.
Important Dates
The next estimated earnings date is Tuesday, May 20, 2025, after market close.
| Earnings Date | May 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Immix Biopharma has 27.72 million shares outstanding. The number of shares has increased by 51.33% in one year.
| Current Share Class | 27.72M |
| Shares Outstanding | 27.72M |
| Shares Change (YoY) | +51.33% |
| Shares Change (QoQ) | +0.46% |
| Owned by Insiders (%) | 21.06% |
| Owned by Institutions (%) | 12.71% |
| Float | 17.97M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 6.07 |
| P/TBV Ratio | 6.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.80, with a Debt / Equity ratio of 0.11.
| Current Ratio | 1.80 |
| Quick Ratio | 1.71 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -112.34% and return on invested capital (ROIC) is -69.10%.
| Return on Equity (ROE) | -112.34% |
| Return on Assets (ROA) | -50.17% |
| Return on Invested Capital (ROIC) | -69.10% |
| Return on Capital Employed (ROCE) | -205.65% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$995,091 |
| Employee Count | 21 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Immix Biopharma has paid $42,020 in taxes.
| Income Tax | 42,020 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.13% in the last 52 weeks. The beta is 0.26, so Immix Biopharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.26 |
| 52-Week Price Change | -4.13% |
| 50-Day Moving Average | 1.75 |
| 200-Day Moving Average | 1.87 |
| Relative Strength Index (RSI) | 61.41 |
| Average Volume (20 Days) | 59,803 |
Short Selling Information
The latest short interest is 221,217, so 0.80% of the outstanding shares have been sold short.
| Short Interest | 221,217 |
| Short Previous Month | 191,305 |
| Short % of Shares Out | 0.80% |
| Short % of Float | 1.23% |
| Short Ratio (days to cover) | 3.90 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -21.77M |
| Pretax Income | -18.18M |
| Net Income | -20.90M |
| EBITDA | -21.70M |
| EBIT | -21.77M |
| Earnings Per Share (EPS) | -$0.70 |
Full Income StatementBalance Sheet
The company has $15.92 million in cash and $1.06 million in debt, giving a net cash position of $14.86 million or $0.54 per share.
| Cash & Cash Equivalents | 15.92M |
| Total Debt | 1.06M |
| Net Cash | 14.86M |
| Net Cash Per Share | $0.54 |
| Equity (Book Value) | 9.59M |
| Book Value Per Share | 0.34 |
| Working Capital | 7.47M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$12.45 million and capital expenditures -$943,480, giving a free cash flow of -$13.40 million.
| Operating Cash Flow | -12.45M |
| Capital Expenditures | -943,480 |
| Free Cash Flow | -13.40M |
| FCF Per Share | -$0.48 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |